CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer Meeting Abstract


Authors: Morris, M. J.; Kiess, A. P.; Nordquist, L.; Gupta, S.; George, D. J.; Messmann, R. A.; Kantoff, P. W.; Nauseef, J. T.; Bander, N. H.; Antonarakis, E. S.
Abstract Title: CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer
Meeting Title: 2025 ASCO Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 43
Issue: 5 Suppl.
Meeting Dates: 2025 Feb 13-15
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2025-02-10
Language: English
ACCESSION: WOS:001454810200025
DOI: 10.1200/JCO.2025.43.5_suppl.TPS289
PROVIDER: wos
Notes: Meeting Abstract: TPS289 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Morris
    577 Morris